help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Norton, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Norton, L.
The Oncologist, Vol. 6, Suppl 3, 30-35, June 2001
© 2001 AlphaMed Press

SUPPLEMENT

Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant Therapy

Larry Norton

Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Larry Norton, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021-6007, USA. Telephone: 212-639-6425; Fax: 212-717-3743; e-mail: nortonl{at}mskcc.org.

The proven benefits of adjuvant chemotherapy on disease-free and overall survival in breast cancer can be explained by concepts of cell kill. Interventions which result in greater log kill can be expected to produce improved clinical results. The application of log-kill concepts to human breast cancer growth, which appears to follow Gompertzian kinetics, suggests not only that the use of non-cross-resistant drugs is important, but that dose-dense schedules may have an advantage over conventional schedules of drug administration. Sequential therapy may allow dose-dense administration of cytotoxic agents and encourage the integration of new biological agents into combination regimens, particularly with the taxanes. Ongoing trials in these concepts are reviewed.

Key Words. Adjuvant • Breast cancer • Gompertzian • Log kill • Paclitaxel • Docetaxel • Herceptin




This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Fountzilas, U. Dafni, H. Gogas, H. Linardou, H. P. Kalofonos, E. Briasoulis, D. Pectasides, E. Samantas, D. Bafaloukos, G. P. Stathopoulos, et al.
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
Ann. Onc., May 1, 2008; 19(5): 853 - 860.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Gonzalez-Angulo and G. N. Hortobagyi
Optimal Schedule of Paclitaxel: Weekly Is Better
J. Clin. Oncol., April 1, 2008; 26(10): 1585 - 1587.
[Full Text] [PDF]

Home page
 JCOHome page
D. Dingli, J. M. Pacheco, G. S. Nowakowski, S. K. Kumar, A. Dispenzieri, S. R. Hayman, M. Q. Lacy, D. A. Gastineau, and M. A. Gertz
Relationship Between Depth of Response and Outcome in Multiple Myeloma
J. Clin. Oncol., November 1, 2007; 25(31): 4933 - 4937.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
N. U. Lin, R. Gelman, and E. P. Winer
Dose Density in Breast Cancer: A Simple Message?
J Natl Cancer Inst, December 7, 2005; 97(23): 1712 - 1714.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Fountzilas, D. Skarlos, U. Dafni, H. Gogas, E. Briasoulis, D. Pectasides, C. Papadimitriou, C. Markopoulos, A. Polychronis, H. P. Kalofonos, et al.
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
Ann. Onc., November 1, 2005; 16(11): 1762 - 1771.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Gluck
Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin
Oncologist, November 1, 2005; 10(10): 780 - 791.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Norton
Conceptual and Practical Implications of Breast Tissue Geometry: Toward a More Effective, Less Toxic Therapy
Oncologist, June 1, 2005; 10(6): 370 - 381.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Tabernero, M. A. Climent, A. Lluch, J. Albanell, J. B. Vermorken, A. Barnadas, A. Anton, C. Laurent, J. I. Mayordomo, N. Estaun, et al.
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
Ann. Onc., September 1, 2004; 15(9): 1358 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Crown, M. O'Leary, and W.-S. Ooi
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
Oncologist, June 2, 2004; 9(suppl_2): 24 - 32.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Takimoto and E. K. Rowinsky
Dose-Intense Paclitaxel: Deja Vu All Over Again?
J. Clin. Oncol., August 1, 2003; 21(15): 2810 - 2814.
[Full Text] [PDF]

Home page
 JCOHome page
M. J. Piccart-Gebhart
Mathematics and Oncology: A Match for Life?
J. Clin. Oncol., April 15, 2003; 21(8): 1425 - 1428.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. G. Estevez, J. M. Cuevas, A. Anton, J. Florian, J. M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, and J. Fortes
Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study
Clin. Cancer Res., February 1, 2003; 9(2): 686 - 692.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.